{
  "name" : "dacemirror.sci-hub.se_journal-article_e873b7d61c53a6b4d750375f2d56b43f_xiong2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer",
    "authors" : [ "Yang Xiong", "Ying Wang" ],
    "emails" : [ "xyxnb@126.com." ],
    "sections" : [ {
      "heading" : null,
      "text" : "Colorectal cancer (CRC) is predicted to be the second leading cause of cancer-related death in United States in 2019. Immunotherapies such as checkpoint inhibitors have proven efficacy in patients with high level of microsatellite instability and refractory to routine chemotherapy. Despite this, immunotherapy-based treatment is seriously limited by cancer immunogenicity which has evolved to evade immune surveillance in many circumstances. Efforts are made by researchers using nanoparticles (NPs) to override cancer-mediated immunosuppression, induce immune response against cancer cells or even generate memory immune cells for long-term disease control. These engineered NPs offer great opportunities in delivering cancer immunotherapy due to their unique properties, such as a high drug/ antigen loading capacity, adjustable particle size, and versatile surface modification. In this review, we will highlight recent researches on the initiation and development of CRC, the immune microenvironment of CRC, and recent trends in engineering novel NPs-based immunotherapies in the treatment of CRC. This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).\nKey words: Colorectal cancer; Tumor immune microenvironment; Immunotherapy; Nanoparticles\nColorectal cancer (CRC) is one of the deadliest cancers, with approximately 100,000 new cases resulting in 50,000 deaths annually in the United States. Despite advances made in detection and treatment over the past decades [1–4] resulting in a steady decline in CRC mortality rates, the 5-year survival rate for colorectal cancer that has metastasized is only 12% [5–7]. In recent years, studies of the relationship between cancer and immune system have led to several clinical trials [8–10] of cancer immunotherapy enabling the immune system to mount an immune response against tumor cells. The composition of intestinal microbiomes has been associated with various\nAcknowledgment Conflict of interest ⁎Corresponding author at: Gaoke Road, Fuchun Street, Fuyang District,\nHangzhou, Zhejiang, China. E-mail address: xyxnb@126.com. (Y. Xiong). 1 Yang Xiong and Ying Wang contributed equally.\nhttps://doi.org/10.1016/j.nano.2019.102034 1549-9634/This is an open access article under the CC BY-NC-ND license.\ndiseases, such as colitis [11–13], irritable bowel disease [14], and CRC [15,16], where micro-organisms can potentially create a favorable microenvironment for disease progression. Evidence suggests the involvement of changes in tumor microenvironment, especially through changes in intestinal microbiomes in the development and progression of CRC in addition to genetic mutations. Therefore, the immune microenvironment of CRC is an important factor affecting cancer immunotherapy. Various immunotherapy strategies can be used to promote the immune response against cancer cells. In recent studies, targeting checkpoint blockade pathways to enhance antitumor response has proved promising for generating tumor-specific T cell response. PD-1 and PD-L1 targeted antibodies such as Pembrolizumab, Nivolumab, and Atezolizumab have been approved by the Food and Drug Administration for cancer therapy [17]. However, considering the therapeutic efficacy and off-target side effects of monoclonal antibodies [18,19], researchers have focused on immunotherapy based on the\nThis is an open access article under the CC BY-NC-ND license (http://\nnanoparticles (NPs) due to their unique properties, such as high carrier capacity, adjustable particle size, and ease of modification for various delivery demands, and feasibility of variable routes of administration [20–22]. In this review, we highlight the recent researches on the initiation and development of CRC, the immune microenvironment of CRC, and recent trends in engineering novel NPs-based immunotherapies in the treatment of CRC."
    }, {
      "heading" : "Progression of colorectal cancer",
      "text" : "The development of CRC typically begins with the transition from a normal epithelium to an abnormal proliferative epithelium [23–25]. The essential stages of CRC development include the formation of aberrant polyps, adenomas, and carcinomas (Figure 1). In general, colorectal tumorigenesis is initiated by genetic mutations and inflammatory immunological factors that can shape a tumorigenic microenvironment. Mutations in oncogenes and tumor suppressor genes result in the activation of Wnt/βcatenin signaling [26,27], which is important for controlling cell proliferation. Activation of β-catenin signaling transforms the epithelium into hyperproliferative state which causes development of aberrant epithelial architecture and polyps. With\ncontinued malignant growth, additional genetic mutations (such as mutations in p53 and K-Ras) mediate the transition of polyps to adenomas, and then to colorectal carcinomas [28,29].\nClinical data suggest that the development of CRC is strongly influenced by inflammatory signals in the colon, and patients with inflammation have an increased risk of the transition to an abnormal colon epithelium which may result in CRC progression [30,31]. Additionally, many CRC patients also exhibit inflammatory infiltration and elevated expression of pro-inflammatory cytokines. Some reports have demonstrated that the immune microenvironment and inflammatory cytokines in the colon play a major role in promoting the development of CRC [32,33]. A majority of CRC tumors display the activation of inflammatory signaling pathways, such as Signal Transducer and Activator of Transcription 3 (STAT3), cyclooxygenase-2 (Cox-2), and Nuclear Factor (NF-κB) pathways [34–37].\nImmune microenvironment in colorectal cancer\nImmune homeostasis is essential for the normal functioning of the immune system [38]. CRC development produces tumor antigens that can be recognized by the immune system resulting in various types of immune cells infiltrating to the tumor site. But\n3Y. Xiong et al / Nanomedicine: Nanotechnology, Biology, and Medicine 21 (2019) 102034\nif the expression of major histocompatibility complexes (MHCs) and tumor-associated antigens is low, the immune system cannot effectively recognize the tumor cells. Moreover, tumor cells produce transforming growth factor-β (TGF-β), IL-10 and other immunosuppressive cytokines, which can lead to an immunosuppressive tumor microenvironment in the tumor [39–41].\nImmune response can be categorized as innate immune response and adaptive immune response. As part of the innate immune response, natural killer (NK) cells recognize and respond to tumor cells providing an immediate defense against tumor cell invasion. Tumor-associated macrophages, dendritic cells (DCs), and mast cells also contribute to tumor antigen recognition and presentation [42]. However, unlike the adaptive immune system, the innate immune system only provides a short-term response to tumor cells. The antigen presenting cells, especially DCs can capture and present tumor antigens to T lymphocytes, which are a major part of the adaptive immune response. In particular, the CD8+ cytotoxic T lymphocytes (CTLs) can kill tumor cells and play an important role in antitumor efficacy [43,44]. Tumor antigens can also be recognized by B cells, which produce tumor-specific antibodies with the help of T helper cells to suppress tumor progression.\nThe CRC microenvironment becomes progressively immunosuppressive due to regulation of immune response activated by tumor invasion, which helps tumor cells evade the immune response. In advanced CRC, malignant tumors recruit regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which help suppress antitumor immune response and promote tumor progression [45]. For example, Tregs can produce immunosuppressive cytokines TGF-β and interleukin-10 (IL10) to suppress cytotoxic T cell response and maintain immune tolerance [46–48]. As tumor progresses, immunosuppressive cells play a more dominant role compared to cytotoxic immune cells (effector CD8+ T cells, NK cells or effector CD4+ T cells). In addition, several inhibitory receptors like Programmed Death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) are known to be expressed on the surface of T cells [49,50]. Programmed Death Ligand-1 (PD-L1) which is constitutively expressed on the surface of cancer cells can bind to PD-1 inducing the suppression of immune response, indicating the cancer cell's attempt to evade cytotoxic immune cells.\nIn conclusion, accumulating evidence indicates that an immunosuppressive microenvironment is a critical barrier for the antitumor immunity in CRC development. It is thus important to modulate the immune microenvironment to inhibit the tumor-promoting immune response and promote immunity against colorectal cancer cells.\nWhat factors influence the immune microenvironment in CRC?\nRole of inflammation in colorectal tumor immune microenvironment\nDuring CRC progression from a single abnormal cell to a developed tumor tissue, localized inflammation in the colon can enhance carcinogenesis by activating pro-inflammatory signaling pathways. These inflammatory signals promote angiogenesis\nand suppress immune-mediated tumor elimination. In this review, we will focus on the transcription factor Nuclear Factor-κB (NF-κB) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathways.\nThe five NF-κB family members p52/p100, p50/p105, c-Rel, RelA/p65, and RelB [51] function as dimeric transcription factors regulating gene expression and influence processes involving inflammation and immunity [52,53]. The up- or down-regulation of NF-κB is based on stimuli in the tissue microenvironment. Activation of NF-κB in the tumor site results in production of proinflammatory cytokines like IL-6 and IL-1, promoting the proliferation and survival of cancer cells [36,53]. NF-κB also regulates the expression of tumor necrosis factor (TNF) and cyclooxygenase 2 (COX-2), which are overexpressed in an inflammatory CRC microenvironment [54,55]. The cytokine TNF, induced by the NF-κB signaling amplifies the activation of the NFκB pathway, thereby promoting tumor growth. COX-2, an enzyme that produces prostaglandins, can enhance tumor promoting inflammation and prevent the activation of type I Interferon (IFN). Loss of IFNs induces the infiltration of MDSCs and Tregs [56,57] and the presence of these immunosuppressive cells limits the efficacy of cytotoxic CD8+ T lymphocytes and shapes a tumor immunosuppressive microenvironment [58–60].\nSTAT3 is another transcription factor that is particularly important in the development of CRC [61,62] and active STAT3 is highly expressed during CRC progression. Tumor-associated immunosuppressive factors like IL-10 can impair maturation of DCs, thereby decreasing the cytotoxic T lymphocytes infiltrating into the tumor, which is also related to the immunosuppressive microenvironment [37,63,64]. The regulation and function of proinflammatory signaling and cytokines highlight the role of inflammation in the colon in shaping the tumor immune microenvironment.\nAssociation of specific microbes with immune system in CRC\nRecent work has highlighted the importance of microbes in the gastrointestinal tract in human health and disease [65,66]. The microbial composition and functions are dynamic and dependent on the status of intestinal microenvironment. Through microbe-free or antibiotic treatedmousemodels, it has been demonstrated that tumor growth is influenced by the microbiomes [67,68]. While some microbes can promote tumor progression, others can promote an antitumor response and the specificmicrobiome can shape the tumor microenvironment. Changes in microbial composition in the human body, resulting from antibiotic treatment, gastrointestinal inflammation, or cancer can cause dysbiosis. Dysbiosis leads to NF-κB activation, which plays a key role in developing the tumor immunosuppressive microenvironment as described before [65]. Bacteria such as A. Muciniphila and Ruminococcaceae have been reported to generate a homeostatic commensal system and prevent formation of an immunosuppressive environment [69,70]. This relationship between the microbiome and immune microenvironment in CRC is complex and remains to be disentangled. Current understanding into the connection between microbes and immune microenvironment in CRC is still limited, and the contribution of microbes to tumor microenvironment still needs to be fully elucidated. However, the importance of microbes in modulating\n4 Y . X iong et al / N anom edicine: N anotechnology, B iology, and M edicine 21 (2019) 102034\nLipid-protamine-DNA (LPD) NPs Deliver PD-L1 trap plasmid for immune checkpoint blockade therapy to reduce the side effect induced by anti-PD-L1 mAb and enhance the antitumor efficacy in the tumor sites\nPD-L1 trap-loaded in LPD NPs\nOVA, and tumor antigens and more efficient delivery in vivo for PDT and immunological therapy NPs This NP vaccine can inhibit tumor growth and extend the survival of CT26-bearing mice\nGraphene oxide (GO) nanosheets\nGO can simultaneously activate toll-like receptor (TLR)-4 and -9 responses in macrophages and CT26 colorectal cancer cells, thereby stimulating the immune cell infiltration inside the tumor\nGraphene oxide\nGO not only suppresses the tumor progression but also enhances cell death, autophagy, and immune responses within the CRC tumor bed 102\nLiposomal nanohybrid cerasomes The liposomal nanohybrid cerasomes are targeted to PD-L1, loaded with paclitaxel, and labeled with IRDye800CW and the MRI contrast agent of Gd-DOTA (PD-L1-PCI-Gd)\nLiposomal nanohybrid cerasomes\nThis cerasomes performed dual-modality fluorescence and MRI imaging to monitor the therapeutic efficacy and optimze the treatments based on immune checkpoints\n115\nMetal-organic framework A nanoscale metal-organic framework (Fe-TBP) is developed from iron-oxo clusters and porphyrin ligands as a novel nanophotosensitizer to overcome the hypoxia and sensitize the immune checkpoint inhibition therapy\nFe-TBP nanorice Fe-TBP mediated PDT induced cytotoxic T cell infiltration and significantly improved the efficacy of anti-PD-L1 and elicited abscopal effects in a CRC mouse model\n117\nGold NPs A polydopamine-coated gold NPs (SGNP@PDA) is developed as a new photothermal agent for PTT therapy and synergistic combination with chemotherapy\nSGNP@PDA\nChemo-PTT combination therapy can induce robust antitumor immunity and eliminate primary and distant untreated tumors in CT26 CRC mouse models, indicating that the impact of chemo-PTT on the innate and adaptive immune response\n118\nBinary cooperative prodrug NPs (BCPNs)\nBCPNs are constructed from an acidic/redox dual responsive oxaliplatin prodrug and the IDO inhibitor to improve the antitumor immunity and decrease the immune-related side effects\nBCPNs BCPNs showed much higher antitumor efficacy than free drug or the combination of free drug in the CRC mouse model, indicating the synergistic effect of oxaliplatin and IDO inhibitors on modulating immune tumor microenvironment\n126\nMesoporous γ-AlOOH nanorods (MANRs)\nMANRs are constructed with open windows at the edges, and oxyhydroxide layer that can utilize as carriers and adjuvants for cancer immunotherapy\nMANRs Compared with commercial aluminum, MANRs showed a higher encapsulation of cancer antigens, stronger intracellular uptake by macrophage-like cells, and markedly elevated the level of CD4+ and CD8+ T cell in CRC\n99 5 Y . X iong et al / N anom edicine: N anotechnology, B iology, and M edicine 21 (2019) 102034\nthe CRC immune microenvironment cannot be ignored. Nanostrategy based therapies to modulate the types and functions of microbes to influence downstream signaling pathways may potentially become a promising alternative for antitumor immunity.\nNanotechnology-mediated delivery approaches for colorectal cancer immunotherapy\nThe advantages of nanoparticle as a versatile carrier for cancer immunotherapy\nNPs have attracted increasing attention and exhibit great promise in the field of cancer immunotherapy. NPs utilized as carriers can deliver immune cargo, such as antigens, gene therapeutics, and proteins to the desired site. Compared to conventional immunotherapy, NP-based immunotherapy pro-\nmotes a stronger immune response, and has higher specificity and efficacy [71,72]. Due to their nanostructure, strong adjuvant property and easily modified surface, NPs can effectively deliver encapsulated immune cargo to the desired cells via targeted or stimuli-responsive delivery strategies. NPloaded antigens showed enhanced immune response when compared to conventional soluble antigens [73,74]. Immune cargo loaded NPs that are locally internalized into APCs can trigger both T cell and B cell mediated immune response through various signaling pathways.\nIn the last decade, NP-based cancer immunotherapy has emerged as an alternative and various NPs like lipid NPs, polymeric NPs, inorganic NPs and virus-like NPs have been designed for advanced nanoimmunotherapy. Table 1 summarized the representative nanoimmunotherapy for CRC. When used in cancer immunotherapy, NPs function via three main\nstrategies: (1) they can locally deliver immune components to the APCs with high efficiency; (2) they themselves can act as an adjuvant or co-deliver an adjuvant along with the antigen to increase the antitumor immune response; (3) they can locally deliver immune-regulating agents to the tumor cells to modulate the tumor immune microenvironment.\nDelivery of antigen and adjuvant as nanovaccines\nTumor cells express antigens that are not normally expressed in healthy tissue. Recognition of these antigens by the immune system stimulates an immune response to eliminate tumor cells, which is crucial for antitumor immunotherapy. Due to the highly specific nature of antigen recognition and excellent immune cell memory response, cancer vaccine is becoming a promising approach for antitumor immunity. Cancer vaccines activate the antigenspecific immune system by enhanced recognition of tumorspecific antigens to eradicate tumor cells. The first therapeutic cancer vaccine, Sipuleucel-T (Provenge®), was approved by the U.S. FDA for metastatic castration-resistant prostate cancer therapy in 2010 [75]. Cancer-specific mutant neoanti-\ngen vaccines exhibit an impressive antitumor immunity, as evidenced in melanoma patients administered therapeutic neoantigen vaccines. More neoantigen vaccines are expected to reach the clinic in the coming years. However, only a few antigens or adjuvants can efficiently activate DCs [72,76] and there are side effects from the presence of antigens at low levels in healthy tissue. Efficient delivery of antigens and adjuvants is also an additional challenge of cancer vaccines. The two factors that determine vaccine efficacy are the internalization of vaccine into DCs; and the transport of activated DCs to lymphatic tissues for stimulation of antigen specific T cells. NP-based vaccines can be specifically targeted to lymphatic tissues without an adverse immune response and the distribution of NPs vaccines in lymph node can also be tuned by modifying particle size. While intravenously injected vaccine is mainly distributed in the spleen, subcutaneous administration can improve vaccine transport to the draining lymph nodes. Here, we highlight recent advances in NP based cancer vaccine for CRC treatment.\nImmunologic adjuvants are used to enhance the efficacy of immune response to provide long-lasting protection or modify\nthe immune response to particular types of immune cells such as T cells instead of other immunosuppressive cells. Lipopolysaccharides (LPS), CpG, and dsRNA used as adjuvants for many vaccines [77,78], stimulate the TLR signaling pathway and produce pro-inflammatory cytokines and trigger the secretion of type I IFNs increasing the host's immune response against antigens. Different types of NPs including PLGA [79,80], lipid-based nanocarriers [81,82], polymers [83,84] or micelles [85] have been reported to show similar results to adjuvants for cancer vaccination. Many inorganic materials used in NP formation such as carbon, silica and aluminum/iron oxide can serve as adjuvants to generate innate immune responses [86–90]. For example, aluminum salts are approved for human use as an adjuvant [91]. The size of NPs plays an important role in delivery of antigens and adjuvants to tumor draining lymph nodes (TDLNs) and it has been shown that NPs ranging from 20 to 100 nm in diameter can selectively accumulate in TDLNs [92]. Zhu et al developed an albumin-binding nanovaccines (AlbiVax) conjugated with Evans blue (EB), which can self-assemble in vivo into albumin nanocomplex with endogenous albumin (Figure 2).\nThese albumin/AlbiVax nanoparticles (about 13 nm diameter size) can co-deliver CpG and antigens into lymph nodes (LNs) efficiently. Tumor growth was specifically inhibited in colorectal tumor bearing mice due to the antigen-specific CD8+ cytotoxic T lymphocytes stimulated by this nanocomplex. Moreover, in combination with PD-1 antibody and/or Abraxane therapy, AlbiVax further eradicates most MC38 tumors, indicating potential synergistic effects of combination cancer immunotherapy [93]. Xu et al designed an upconversion NP (UCNP) based on 20% Yb and 2% Er-doped NaYF4, simultaneously encapsulating Chlorin e6 (Ce6, a photosensitizer for PDT), and imiquimod (R837, a Toll-like recptor-7 agonist) as an adjuvant. These UCNP-Ce6-R837 nanovaccines with enhanced tissue penetration depth and NIR-triggered PDT can destroy tumor cells and promote strong antitumor immune responses by triggering the maturation of DCs and secretion of cytokines. Further, UCNP-Ce6-R837 in combination with CTLA-4 checkpoint blockade therapy, showed strong antitumor immunities to inhibit the growth of distant tumors (Figure 3) [94]. This group also developed a poly(lactic-co-glycolic) acid (PLGA) NP coencapsulated delivery system for effective cancer\n9Y. Xiong et al / Nanomedicine: Nanotechnology, Biology, and Medicine 21 (2019) 102034\nimmunotherapy by combining photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade therapy [95].\nEphA2-derived peptide in combination with amphiphilic nanoparticles has been developed as an adjuvant for boosting immune system against colorectal cancer liver metastasis. This peptide can improve the binding to MHC and enhance the interaction with the TCR. The results demonstrate strong and specific cytotoxic activity against CRC cells and little damage to liver and kidney due to the local distribution of these NPs [96]. Ultra-pH-sensitive (UPS) NPs (20-50 nm in diameter) containing tertiary amines have been reported to be a good nanocarrier of antigens [97]. OVA-loaded NPs efficiently delivered antigen to TDLNs and generated a strong OVA-specific cytotoxic T cell response with type I interferon release. Luo et al demonstrate that the effect of this nanovaccine is dependent on the stimulator of interferon genes (STING) pathway, and a STING-activating NPvaccine could be a simple and effective strategy in antitumor immunity.\nRecently, research has been focused on developing multifunctional NPs that can co-deliver tumor antigens and adjuvants to the same immune cells, thus resulting in a strong immune response. Kuai et al report an application of phospholipids and apolipoprotein A1 (ApoA1)-mimetic peptides based nanodiscs for co-delivery of neoantigen peptides and adjuvants [98]. This high-density lipoprotein-mimicking nanodisc can markedly improve the delivery efficacy of antigen and adjuvant to the lymphoid organs and present antigens on dendritic cells, thereby enhancing antitumor immunity. They also report that 47-fold and 31- fold greater frequencies of neoantigen-specific CTLs were observed compared to soluble vaccines and CpG adjuvant respectively, indicating the excellent immune response of this nanovaccine. This study also demonstrated the in vivo antitumor activity through combination therapy of both nanodisc and anti-PD-1/anti-CTLA-4 antibody. Lipid-calcium phosphate (LCP) NPs can also be used as an effective carrier for antigen and adjuvants co-delivery. Huang et al constructed three potent vaccine formulations based on LCP NPs to investigate the antitumor efficacy of different adjuvants [99]. In this study, phosphorylated adjuvants, CpG, 2′3'cGAMP, and 5'pppdsRNA were loaded into LCP NPs, coupled with a tumor specific peptide antigen (p-AH1-A5) and the antitumor efficacy was measured in orthotopic colorectal liver metastasis tumor-bearing mice. The results demonstrated that the adjuvant 5'pppdsRNA (RIG-1 ligand) significantly inhibited the growth of the primary colon cancer as well as the liver metastasis.\nDesign of nanoparticles for immune checkpoint inhibition\nSeveral inhibitory receptors such as PD-1 and CTLA-4 are present on the surface of immune cells, which help regulate immune responses in the human body, and specifically prevent autoimmune disease. However, PD-L1, which is constitutively expressed on the surface of many cancer cells, can bind to PD-1 inhibitory receptors and down-regulate immune response of cytotoxic T cells against these cancer cells. Recent studies and clinical trials have demonstrated the therapeutic efficacy of antiPD-1, anti-PD-L1, and anti-CTLA-4 monoclonal antibodies in\ncancer immunotherapy via checkpoint inhibition. However, other immune-related side effects including inflammation and autoimmune disorder have been observed in major healthy organs after the PD-1/PD-L1 and CTLA-4 mAb or small molecular inhibitor therapies in the clinical applications [100,101]. In order to reduce these side effects, various NPbased checkpoint inhibitor delivery systems were developed to target the delivery of immune cargo to desired cells, thereby reducing the off-target side effects and enhancing the therapeutic efficacy of checkpoint inhibitors. Song et al designed a PD-L1 trap plasmid and delivered this plasmid via lipid-protamineDNA (LPD) NPs to locally and transiently express PD-L1 trap protein in the tumor tissue [102]. This LPD based PD-L1 trap has been demonstrated to synergize with oxaliplatin for tumor inhibition. Further, compared to anti-PD-L1 mAb, it did not induce obvious Th17 cell accumulation in the spleen in oxaliplatin combination therapy, suggesting that this NPsbased PD-L1 trap delivery system can decrease the side-effects associated with anti-PD-L1 mAb (Figure 4). Similarly, Goodwin et al found that delivering PD-L1 and CXCL12 trap plasmids to the nucleus of liver hepatocytes via LCP NPs greatly increased the concentration of immunotherapeutic agents in liver tissue and decreased accumulation of immunosuppressive signals, thereby inhibiting the colorectal cancer liver metastasis [103]. Meir et al designed a straightforward approach for fast image-guided prognostic and immune checkpoint inhibition using PD-L1 mAb conjugated gold NPs. This allowed early prediction of response and enhanced the immunotherapy, indicating that this technology can serve as a promising tool for early and noninvasive patient stratification and personalized nanomedicine PD-L1 mAb [104] since only a minority of cancer patients respond to immune checkpoint blockade therapy via PD-1/PDL1 mAb.\nSome reports have shown that small peptides can be promising therapeutics for checkpoint blockade immunotherapy and can help overcome the high cost and poor patient compliance caused by immune checkpoint antibodies. However, peptides have a short blood circulation time, are not stable in serum, and can also have off-target side effects [105]. Therefore, Luo et al constructed a PLGA nanoparticle to load an anti-PD-1 peptide in to a hollow gold nanoshell that served as a photothermal agent. This strategy not only exhibits photothermal antitumor therapy, but also overcomes some of the disadvantages of anti-PD-1 peptide. This combination nanostrategy therapy induced strong immunity and significantly inhibited the colorectal cancer growth [106].\nIndoleamine 2,3-dioxygenase (IDO) is another immune inhibitory factor that suppresses T cell proliferation and induces T cell apoptosis via catalyzing oxidation of tryptophan to kynurenine [107–109]. Therefore, inhibition of IDO can enhance antitumor activity of T cells. Several small molecule IDO inhibitors have been proposed as new drug candidates. However, direct administration of these inhibitors has limited their application due to the degradation, off-target effects, and decreased therapeutic efficacy in the tumor site. Therefore, various nanocarriers have been developed for delivering these small molecular inhibitors. For example, a chlorin-based nanoscale metal-organic framework is constructed to load IDO\n11Y. Xiong et al / Nanomedicine: Nanotechnology, Biology, and Medicine 21 (2019) 102034\ninhibitors with sustained controlled release to tumor sites. This decreases the side effects and increases the drug accumulation in tumor tissue. The controlled release IDO inhibitor can thus modulate the immunosuppressive tumor microenvironment and inhibit tumor growth in CRC mouse models [110].\nNanoparticles for induced immunogenic cell death (ICD)\nRecent studies have shown that tumor cell death can induce an immune response via the activation of APCs and T cells during the chemotherapies, photodynamic therapy, and photothermal therapy. The exposure of calreticulin (CRT) to the cell surface leads to the release of adenosine triphosphate (ATP) and high-mobility group box 1 protein (HMGB1) into the extracellular matrix. This can promote recruitment and activation of APCs and T cells during ICD in tumor tissue. Antitumor immunotherapies based on ICD have been confirmed via chemodrugs, whole-cell vaccines, and photodynamic therapy. Chemo agents such as doxorubicin, mitoxantrone, etoposide, and oxaliplatin have demonstrated antitumor efficacy in the murine colorectal cancer model [111–113]. Therefore, co-delivery of chemo agents as ICD inducers and immune checkpoint inhibitors might be a helpful strategy to boost response of colorectal tumors to checkpoint blockade therapy. Various types of multifunctional NPs that can deliver ICD inducers have been developed for enhancing the immunotherapy response. For example, the nanoscale coordination polymer (NCP) core-shell NPs have been utilized to induce the ICD by encapsulating oxaliplatin in the core and conjugating the photosensitizer pyropheophorbidelipid (pyrolipid) in the shell (NCP@pyrolipid) for effective chemotherapy and photodynamic therapy [114]. Lin et al found that co-delivery of oxaliplatin and pyrolipid resulted in calreticulin exposure on the cell surface and provoked an immune response in the colorectal tumor-bearing mice. When NCP@pyrolipid NPs were combined with αPD-L1 therapy, both light-irradiated primary tumors and non-treated distant tumors were eliminated by inducing a strong tumor-specific immune response. This abscopal effect is evidence to predict immune response, since ICD-based regression of distant tumor results from the treated primary tumor, which further confirms tumorspecific immunotherapy (Figure 5). Song et al also demonstrated excellent antitumor immunotherapy in the orthotopic colorectal tumor model after synergistic therapy between oxaliplatin and PD-L1 inhibition based on LPD NPs [102]."
    }, {
      "heading" : "Conclusion and outlooks",
      "text" : "In this review, we have summarized the recent researches on the initiation and development of CRC, the immune microenvironment of CRC, and the factors that influence the immune microenvironment in CRC. Major advances in CRC immunotherapy have included the approval of anti-PD-1, anti-PD-L1, and anti-CTL4 monoclonal antibodies and several clinical trials are currently in progress. However, majority of CRC patients with microsatellite-stable (MSS) or MMR-proficient disease do not respond to checkpoint blockade therapy due to insufficient activation of the immune system. Strategies combining nanotechnology with immunotherapy have emerged to enhance\nantitumor efficacy. Due to their nanostructure, these NPs can be utilized as carriers of immune cargo to exert antitumor immunity by delivering antigens and adjuvants to TDLN, modulating immune checkpoints, and inducing immunogenic cell death. Here, major advances in NP-mediated immunotherapies for CRC treatment were highlighted. Compared to conventional immunotherapy, NP-based immunotherapy has a stronger immune response and higher specificity and efficacy. Moreover, multifunctional NPs offer the possibility of targeted delivery and simultaneous bioimaging, thus improving the efficacy of immunotherapy and reducing the side-effect caused by nonspecific delivery. Overall, research advances in NP-based immunity are exciting and hold great potential for future biomedical applications. However, several significant challenges still need to be addressed in the war against colorectal cancer. The development of multifunctional NP-based delivery systems with low-toxicity, good biocompatibility and biodegradability is necessary. Moreover, specifically targeting immune cells or other tumor-related functionalized cells combined with real-time bioimaging in tumor tissue will usher in a new field of nanotechnology-based immunotheranostics. Additionally, the connection between microbes and CRC progression cannot be ignored. Even though the contribution of microbes to tumor microenvironment still needs to be fully elucidated, the nanostrategy based therapies to modulate the types and functions of microbes and further influence the downstream signaling pathway are new promising alternative for antitumor immunity. Currently, the regulation of microbiome is focused on the antibiotics utilization [115], which makes broad spectrum compositional changes. NP-based carriers can deliver the live and special bacteria to intestinal tract and locally modulate microbiome and overcome the barriers of gastrointestinal tract as well as maintain the activity of microbiota via appropriate modification and encapsulation strategy. Layer-by-layer (LbL) nanoparticles have been reported to encapsulate and deliver microbes, and protect them against the gastrointestinal tract and maintain their activities [116], which provide the potential to modulate the microbiome for antitumor immunity."
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Colorectal cancer (CRC) is predicted to be the second leading cause of cancer-related death in United States in 2019. Immunotherapies such as checkpoint inhibitors have proven efficacy in patients with high level of microsatellite instability and refractory to routine chemotherapy. Despite this, immunotherapy-based treatment is seriously limited by cancer immunogenicity which has evolved to evade immune surveillance in many circumstances. Efforts are made by researchers using nanoparticles (NPs) to override cancer-mediated immunosuppression, induce immune response against cancer cells or even generate memory immune cells for long-term disease control. These engineered NPs offer great opportunities in delivering cancer immunotherapy due to their unique properties, such as a high drug/ antigen loading capacity, adjustable particle size, and versatile surface modification. In this review, we will highlight recent researches on the initiation and development of CRC, the immune microenvironment of CRC, and recent trends in engineering novel NPs-based immunotherapies in the treatment of CRC. This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).",
    "creator" : "Elsevier"
  }
}